Original Study| Volume 19, ISSUE 2, P162-168, February 2018

Association of Antidementia Drugs and Mortality in Community-Dwelling Frail Older Patients With Dementia: The Role of Mortality Risk Assessment

Published:October 12, 2017DOI:



      To evaluate whether treatment with antidementia drugs is associated with reduced mortality in older patients with different mortality risk at baseline.






      A total of 6818 older people who underwent a Standardized Multidimensional Assessment Schedule for Adults and Aged Persons (SVaMA) evaluation to determine accessibility to homecare services or nursing home admission from 2005 to 2013 in the Padova Health District, Italy were included.


      Mortality risk at baseline was calculated by the Multidimensional Prognostic Index (MPI), based on information collected with the SVaMA. Participants were categorized to have mild (MPI-SVaMA-1), moderate (MPI-SVaMA-2), and high (MPI-SVaMA-3) mortality risk. Propensity score-adjusted hazard ratios (HR) of 2-year mortality were calculated according to antidementia drug treatment.


      Patients treated with antidementia drugs had a significant lower risk of death than untreated patients (HR 0.82; 95% confidence interval [CI] 0.73–0.92 and 0.56; 95% CI 0.49–0.65 for patients treated less than 2 years and more than 2 years treatment, respectively). After dividing patients according to their MPI-SVaMA grade, antidementia treatment was significantly associated with reduced mortality in the MPI-SVaMA-1 mild (HR 0.71; 95% CI 0.54–0.92) and MPI-SVaMA-2 moderate risk (HR 0.61; 95% CI 0.40–0.91, matched sample), but not in the MPI-SVaMA-3 high risk of death.


      This large community-dwelling patient study suggests that antidementia drugs might contribute to increased survival in older adults with dementia with lower mortality risk.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the American Medical Directors Association
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Association Association
        2016 Alzheimer's disease facts and figures.
        Alzheimer Dementia. 2016; 12: 459-509
        • Gambassi G.
        • Lapane K.L.
        • Landi F.
        • et al.
        Gender differences in the relation between comorbidity and mortality of patients with Alzheimer's disease. Systematic Assessment of Geriatric drug use via Epidemiology (SAGE) Study Group.
        Neurology. 1999; 53: 508-516
        • Rountree S.D.
        • Chan W.
        • Pavlik V.N.
        • et al.
        Factors that influence survival in a probable Alzheimer disease cohort.
        Alzheimer Res Ther. 2012; 4: 16
        • Ueki A.
        • Shinjo H.
        • Shimode H.
        • et al.
        Factors associated with mortality in patients with early-onset Alzheimer's disease: A five-year longitudinal study.
        Int J Geriatr Psychiatry. 2001; 16: 810-815
        • Moritz D.J.
        • Fox P.J.
        • Luscombe F.A.
        • Kraemer H.C.
        Neurological and psychiatric predictors of mortality in patients with Alzheimer disease in California.
        Arch Neurol. 1997; 54: 878-885
        • Geldmacher D.S.
        • Provenzano G.
        • McRae T.
        • et al.
        Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease.
        J Am Geriatr Soc. 2003; 51: 937-944
        • Wimo A.
        • Winblad B.
        • Stoffler A.
        • et al.
        Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease.
        PharmacoEconomics. 2003; 21: 327-340
        • Lopez O.L.
        • Becker J.T.
        • Wisniewski S.
        • et al.
        Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease.
        J Neurol Neurosurg Psychiatry. 2002; 72: 310-314
        • Lopez O.L.
        • Becker J.T.
        • Wahed A.S.
        • et al.
        Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.
        J Neurol Neurosurg Psychiatry. 2009; 80: 600-607
        • Gasper M.C.
        • Ott B.R.
        • Lapane K.L.
        Is donepezil therapy associated with reduced mortality in nursing home residents with dementia?.
        Am J Geriatr Pharmacother. 2005; 3: 1-7
        • Zhu C.W.
        • Livote E.E.
        • Scarmeas N.
        • et al.
        Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease.
        Alzheimer Dementia. 2013; 9: 733-740
        • Howes L.G.
        Cardiovascular effects of drugs used to treat Alzheimer's disease.
        Drug Safety. 2014; 37: 391-395
        • Soysal P.
        • Isik A.T.
        • Stubbs B.
        • et al.
        Acetylcholinesterase inhibitors are associated with weight loss in older people with dementia: A systematic review and meta-analysis.
        J Neurol Neurosurg Psychiatry. 2016; 87: 1368-1374
        • Clegg A.
        • Young J.
        • Iliffe S.
        • et al.
        Frailty in elderly people.
        Lancet (London, England). 2013; 381: 752-762
        • Fried L.P.
        • Tangen C.M.
        • Walston J.
        • et al.
        Frailty in older adults: Evidence for a phenotype.
        J Gerontol Ser A Biol Sci Med Sci. 2001; 56: M146-M156
        • Panza F.
        • Seripa D.
        • Solfrizzi V.
        • et al.
        Targeting cognitive frailty: Clinical and neurobiological roadmap for a single complex phenotype.
        J Alzheimers Dis. 2015; 47: 793-813
        • Yourman L.C.
        • Lee S.J.
        • Schonberg M.A.
        • et al.
        Prognostic indices for older adults: A systematic review.
        JAMA. 2012; 307: 182-192
        • Pilotto A.
        • Cella A.
        • Pilotto A.
        • et al.
        Three decades of comprehensive geriatric Assessment: Evidence coming from different healthcare settings and specific clinical conditions.
        J Am Med Dir Assoc. 2017; 18: e1-e11
        • Pilotto A.
        • Ferrucci L.
        • Franceschi M.
        • et al.
        Development and validation of a multidimensional prognostic index for one-year mortality from comprehensive geriatric assessment in hospitalized older patients.
        Rejuvenation Res. 2008; 11: 151-161
        • Pilotto A.
        • Gallina P.
        • Fontana A.
        • et al.
        Development and validation of a Multidimensional Prognostic Index for mortality based on a standardized Multidimensional Assessment Schedule (MPI-SVaMA) in community-dwelling older subjects.
        J Am Med Dir Assoc. 2013; 14: 287-292
        • Pilotto A.
        • Sancarlo D.
        • Panza F.
        • et al.
        The multidimensional prognostic index (MPI), based on a comprehensive geriatric assessment predicts short- and long-term mortality in hospitalized older patients with dementia.
        J Alzheimers Dis. 2009; 18: 191-199
        • Gallucci M.
        • Battistella G.
        • Bergamelli C.
        • et al.
        Multidimensional prognostic index in a cognitive impairment outpatient setting: Mortality and hospitalizations. The Treviso Dementia (TREDEM) study.
        J Alzheimers Dis. 2014; 42: 1461-1468
        • von Elm E.
        • Altman D.G.
        • Egger M.
        • et al.
        The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies.
        J Clin Epidemiol. 2008; 61: 344-349
        • Rosenbaum P.R.
        • Rubin D.B.
        The central role of the propensity score in observational studies for causal effects.
        Biometrika. 1983; 70: 41-55
        • Brodaty H.
        • Seeher K.
        • Gibson L.
        Dementia time to death: A systematic literature review on survival time and years of life lost in people with dementia.
        Int Psychogeriatr. 2012; 24: 1034-1045
        • Onder G.
        • Liperoti R.
        • Foebel A.
        • et al.
        Polypharmacy and mortality among nursing home residents with advanced cognitive impairment: Results from the SHELTER study.
        J Am Med Dir Assoc. 2013; 14: 450.e7-450.e12
        • Ott B.R.
        • Lapane K.L.
        Tacrine therapy is associated with reduced mortality in nursing home residents with dementia.
        J Am Geriatr Soc. 2002; 50: 35-40
        • Winblad B.
        • Black S.E.
        • Homma A.
        • et al.
        Donepezil treatment in severe Alzheimer's disease: A pooled analysis of three clinical trials.
        Curr Med Res Opin. 2009; 25: 2577-2587
        • Nordstrom P.
        • Religa D.
        • Wimo A.
        • et al.
        The use of cholinesterase inhibitors and the risk of myocardial infarction and death: A nationwide cohort study in subjects with Alzheimer's disease.
        Eur Heart J. 2013; 34: 2585-2591
        • Meguro K.
        • Kasai M.
        • Akanuma K.
        • et al.
        Donepezil and life expectancy in Alzheimer's disease: A retrospective analysis in the Tajiri Project.
        BMC Neurol. 2014; 14: 83
        • Vidal J.S.
        • Lacombe J.M.
        • Dartigues J.F.
        • et al.
        Memantine therapy for Alzheimer disease in real-world practice: An observational study in a large representative sample of French patients.
        Alzheimer Dis Assoc Disord. 2008; 22: 125-130
        • Robertson D.A.
        • Savva G.M.
        • Kenny R.A.
        Frailty and cognitive impairment–A review of the evidence and causal mechanisms.
        Ageing Res Rev. 2013; 12: 840-851
        • O’Brien J.T.
        • Burns A.
        Clinical practice with antidementia drugs: A revised (second) consensus statement from the British Association for Psychopharmacology.
        J Psychopharmacol. 2011; 25: 997-1019
        • Takeda A.
        • Loveman E.
        • Clegg A.
        • et al.
        A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
        Int J Geriatr Psychiatry. 2006; 21: 17-28
        • Pilotto A.
        • Sancarlo D.
        • Daragjati J.
        • Panza F.
        Perspective: The challenge of clinical decision-making for drug treatment in older people. The role of multidimensional assessment and prognosis.
        Front Med. 2014; 1: 1-61
        • Kojima G.
        • Taniguchi Y.
        • Iliffe S.
        • Walters K.
        Frailty as a predictor of Alzheimer disease, vascular dementia, and all dementia among community-dwelling older people: A systematic review and meta-analysis.
        J Am Med Dir Assoc. 2016; 17: 881-888
        • Monacelli F.
        • Rosa G.
        Cholinesterase inhibitors: Cardioprotection in Alzheimer's disease.
        J Alzheimers Dis. 2014; 42: 1071-1077
        • Kakinuma Y.
        • Akiyama T.
        • Sato T.
        Cholinoceptive and cholinergic properties of cardiomyocytes involving an amplification mechanism for vagal efferent effects in sparsely innervated ventricular myocardium.
        FEBS J. 2009; 276: 5111-5125
        • Rosas-Ballina M.
        • Tracey K.J.
        Cholinergic control of inflammation.
        J Intern Med. 2009; 265: 663-679
        • White C.S.
        • Lawrence C.B.
        • Brough D.
        • Rivers-Auty J.
        Inflammasomes as therapeutic targets for Alzheimer's disease.
        Brain Pathol (Zurich, Switzerland). 2017; 27: 223-234
        • Pilotto A.
        • Panza F.
        • Copetti M.
        • et al.
        Statin treatment and mortality in community-dwelling frail older patients with diabetes mellitus: A retrospective observational study.
        PloS One. 2015; 10: e0130946
        • Pilotto A.
        • Gallina P.
        • Panza F.
        • et al.
        Relation of statin use and mortality in community-dwelling frail older patients with coronary artery disease.
        Am J Cardiol. 2016; 118: 1624-1630
        • Pilotto A.
        • Gallina P.
        • Copetti M.
        • et al.
        Warfarin treatment and all-cause mortality in community-dwelling older adults with atrial fibrillation: A retrospective observational study.
        J Am Geriatr Soc. 2016; 64: 1416-1424